Published • loading... • Updated
Health Canada Approves the Use of SKYRIZI® (Risankizumab) for the Treatment of Moderate to Severe Plaque Psoriasis in Children and Adolescents
Summary by Les Affaires
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Psoriasis affects 1 million Canadians, and almost one third of people with the disease experience symptoms before
·Montreal, Canada
Read Full ArticleCoverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
